Blood Res.
2023 Dec;58(4):194-200. 10.5045/br.2023.2023206.
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
- Affiliations
-
- 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 2Department of Internal Medicine, Dongsan Medical Center, Daegu, Korea
- 3Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea
- 4Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea
- 5Division of Hematology-Oncology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea
- 6Center of Evidence Based Medicine, Institute of Convergence Science, Yonsei University, Seoul, Korea
- 7Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea
- 8Hematology-Oncology Clinic, National Cancer Center, Goyang, Korea
- 9Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea
- 10Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea
- 11Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Ulsan, Korea
- 12Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
- 13Department of Hematology and Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Korea
- KMID: 2550197
- DOI: http://doi.org/10.5045/br.2023.2023206
Abstract
- Background
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, including mycosis fungoides (MF). However, there are limited data reflecting real-world experiences with BV treatment for HL, ALCL, and MF.
Methods
This was a multicenter, non-interventional registry study of the efficacy and safety of BV in patients with relapsed or refractory CD30-positive lymphoma (CISL1803/BRAVO). Outcomes were determined based on the occurrence of relapse or progression and overall survival after BV treatment.
Results
A total of 85 patients were enrolled in this study. The median number of BV cycles was 10 (range, 2‒16) in the patients with HL. The objective response rate (ORR) of patients with HL to BV was 85.4% (41/48), comprising 27 complete responses (CRs) and 14 partial responses (PRs). The ORR of ALCL was 88% (22/25), consisting of 17 CRs and five PRs, whereas the ORR of MF was 92% (11/12). At the median follow-up of 44.6 months after BV treatment, the median post-BV progression-free survival of HL, ALCL, and MF patients was 23.6 months, 29.0 months, and 16.7 months, respectively (P =0.641). The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades).
Conclusion
The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Brentuximab vedotin: clinical updates and practical guidance
- Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
- CD30＋ Large-Cell Transformation of Mycosis Fungoides Treated with Brentuximab Vedotin
- Efficacy of Brentuximab Vedotin in Relapsed or RefractoryHigh-CD30–Expressing Non-Hodgkin Lymphomas:Results of a Multicenter, Open-Labeled Phase II Trial
- Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant‑eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma
